3 results
Primairy objective: Does the use of daily magnesium oxide reduce the prostate movements during a radiotherapy fraction? Secondary objectives: Does the use of magnesium oxide change the acute toxicity of the treatment? Does the use of magnesium oxide…
Primary objective:* To compare the rates of complete recovery (alive, free of dialysis and return of serum creatinine to <150% of reference baseline; equivalent to acute kidney disease (AKD) category 0) at Day 14 between the Reltecimod-…
To evaluate the safety and tolerability of ascending multiple PO doses of AMG 986 in heart failure patients (Part C).* To characterize AMG 986 pharmacokinetics (PK) after IV infusion and oral administrationin heart failure patients.* To characterize…